Abstract
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. The addition of rituximab to chemotherapy has improved progression-free survival and overall survival for patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Rituximab-CHOP therapy is the new standard therapy in elderly and young, low-risk DLBCL patients. For young, high-risk DLBCL patients, treatment that incorporates rituximab and hematopoietic stem cell transplantation has been administered in clinical studies. Rituximab maintenance therapy for DLBCL is not effective at present. On the other hand, when active treatment is required in patients with follicular lymphoma, rituximab-chemotherapy is now the optimal treatment. In follicular lymphoma, randomized controlled trials of rituximab-chemotherapy show lengthened time to progression but, as yet, no improvement in overall survival.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
